For example, with the activation of FGF18-FGFR2-c-Jun-YAP1 axis, the clinical prognosis of GC moves in an unfavorable direction (53); FGF18 promotes the proliferation of lung cancer cell lines and tumor formation in subcutaneous xenograft models through FGFR1-ERK pathway (127, 129); FGF18 promotes angiogenesis and tumor growth in HCC by enhancing FGFR3 pathway and phosphorylation of AKT-ERK protein, and is regulated upstream by Wnt/β-catenin signaling pathway (79). Here, FGFR3 is linked to hepatocellular carcinoma.